Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518115 · ClinicalTrials.gov registry record · Phase 2
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 361
- Enrollment target
NCT00518115 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 361 participants.
The verdict
NCT00518115, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 361 participants
- Enrollment target
Study Summary
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring of any side effects.
Interventions
- DRUG Albiglutide (GSK716155) or exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00518115
The ClinicalTrials.gov registry entry for NCT00518115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Albiglutide (GSK716155) or exenatide is the first listed.
NCT00518115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00518115 about?
NCT00518115 is a clinical study titled "Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only". This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (...
What is the current status of trial NCT00518115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 361 participants. The study started on 2007-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00518115?
The interventions under investigation include: Albiglutide (GSK716155) or exenatide (DRUG).
Who is sponsoring clinical trial NCT00518115?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.